Alethia Young
Stock Analyst at Cantor Fitzgerald
(4.80)
# 91
Out of 4,414 analysts
100
Total ratings
60.53%
Success rate
48.03%
Average return
Main Sectors:
36 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $937.61 | -9.34% | 7 | Oct 16, 2023 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | $46 | $15.50 | +196.77% | 4 | Sep 12, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $16.62 | +8.30% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $16.51 | +263.42% | 3 | Sep 7, 2023 | |
| LBPH Longboard Pharmaceuticals | Reiterates: Overweight | $16 | $22.81 | -29.86% | 5 | Aug 22, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $2.30 | +291.30% | 2 | Aug 22, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | $79 → $47 | $24.13 | +94.78% | 3 | Aug 8, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $10.36 | +228.19% | 2 | Jul 6, 2023 | |
| NEXI NexImmune | Downgrades: Neutral | n/a | $3.12 | - | 2 | Nov 16, 2022 | |
| BIIB Biogen | Maintains: Neutral | n/a | $213.51 | - | 4 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $10.00 | +200.00% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | n/a | $8.13 | - | 1 | Jun 14, 2021 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | n/a | $400.16 | - | 3 | Jun 11, 2021 | |
| AKBA Akebia Therapeutics | Initiates: Overweight | n/a | $1.30 | - | 1 | Mar 8, 2021 | |
| FATE Fate Therapeutics | Maintains: Overweight | n/a | $4.10 | - | 1 | Feb 25, 2021 | |
| AMGN Amgen | Maintains: Overweight | n/a | $278.39 | - | 6 | Feb 3, 2021 | |
| BCYC Bicycle Therapeutics | Initiates: Overweight | n/a | $24.69 | - | 1 | Oct 12, 2020 | |
| GILD Gilead Sciences | Maintains: Overweight | n/a | $65.33 | - | 2 | Aug 19, 2020 | |
| TGTX TG Therapeutics | Maintains: Overweight | n/a | $16.42 | - | 1 | May 6, 2020 | |
| MRNS Marinus Pharmaceuticals | Reiterates: Overweight | n/a | $1.45 | - | 1 | May 5, 2020 | |
| ASND Ascendis Pharma | Reiterates: Overweight | n/a | $141.10 | - | 5 | Apr 20, 2020 | |
| PTCT PTC Therapeutics | Reiterates: Overweight | n/a | $33.62 | - | 3 | Apr 8, 2020 | |
| PACB Pacific Biosciences of California | Assumes: Overweight | n/a | $1.76 | - | 1 | Mar 9, 2020 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Overweight | n/a | $5.17 | - | 1 | Mar 6, 2020 | |
| SRPT Sarepta Therapeutics | Reiterates: Overweight | n/a | $130.63 | - | 7 | Feb 27, 2020 | |
| AGIO Agios Pharmaceuticals | Reiterates: Overweight | n/a | $34.58 | - | 4 | Feb 14, 2020 | |
| INCY Incyte | Maintains: Neutral | n/a | $53.09 | - | 2 | Jan 3, 2020 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $26.34 | - | 2 | Jul 19, 2018 | |
| MESO Mesoblast | Downgrades: Underperform | n/a | $7.29 | - | 3 | Mar 22, 2018 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | n/a | $150.31 | - | 3 | Mar 13, 2018 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | n/a | $83.80 | - | 2 | Mar 2, 2018 | |
| PBYI Puma Biotechnology | Maintains: Outperform | n/a | $4.96 | - | 4 | Jan 24, 2018 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | n/a | $23.27 | - | 1 | Nov 3, 2017 | |
| DRI Darden Restaurants | Maintains: Neutral | n/a | $147.86 | - | 1 | Sep 27, 2017 | |
| UTHR United Therapeutics | Initiates: Underperform | n/a | $258.13 | - | 1 | Mar 16, 2017 | |
| ACIU AC Immune | Initiates: Outperform | n/a | $2.44 | - | 1 | Oct 18, 2016 |
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $937.61
Upside: -9.34%
Arcus Biosciences
Sep 12, 2023
Reiterates: Overweight
Price Target: $46
Current: $15.50
Upside: +196.77%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $16.62
Upside: +8.30%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $16.51
Upside: +263.42%
Longboard Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $22.81
Upside: -29.86%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $2.30
Upside: +291.30%
Arrowhead Pharmaceuticals
Aug 8, 2023
Maintains: Overweight
Price Target: $79 → $47
Current: $24.13
Upside: +94.78%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $10.36
Upside: +228.19%
NexImmune
Nov 16, 2022
Downgrades: Neutral
Price Target: n/a
Current: $3.12
Upside: -
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: n/a
Current: $213.51
Upside: -
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $10.00
Upside: +200.00%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: n/a
Current: $8.13
Upside: -
Vertex Pharmaceuticals
Jun 11, 2021
Maintains: Overweight
Price Target: n/a
Current: $400.16
Upside: -
Akebia Therapeutics
Mar 8, 2021
Initiates: Overweight
Price Target: n/a
Current: $1.30
Upside: -
Fate Therapeutics
Feb 25, 2021
Maintains: Overweight
Price Target: n/a
Current: $4.10
Upside: -
Amgen
Feb 3, 2021
Maintains: Overweight
Price Target: n/a
Current: $278.39
Upside: -
Bicycle Therapeutics
Oct 12, 2020
Initiates: Overweight
Price Target: n/a
Current: $24.69
Upside: -
Gilead Sciences
Aug 19, 2020
Maintains: Overweight
Price Target: n/a
Current: $65.33
Upside: -
TG Therapeutics
May 6, 2020
Maintains: Overweight
Price Target: n/a
Current: $16.42
Upside: -
Marinus Pharmaceuticals
May 5, 2020
Reiterates: Overweight
Price Target: n/a
Current: $1.45
Upside: -
Ascendis Pharma
Apr 20, 2020
Reiterates: Overweight
Price Target: n/a
Current: $141.10
Upside: -
PTC Therapeutics
Apr 8, 2020
Reiterates: Overweight
Price Target: n/a
Current: $33.62
Upside: -
Pacific Biosciences of California
Mar 9, 2020
Assumes: Overweight
Price Target: n/a
Current: $1.76
Upside: -
Aurinia Pharmaceuticals
Mar 6, 2020
Maintains: Overweight
Price Target: n/a
Current: $5.17
Upside: -
Sarepta Therapeutics
Feb 27, 2020
Reiterates: Overweight
Price Target: n/a
Current: $130.63
Upside: -
Agios Pharmaceuticals
Feb 14, 2020
Reiterates: Overweight
Price Target: n/a
Current: $34.58
Upside: -
Incyte
Jan 3, 2020
Maintains: Neutral
Price Target: n/a
Current: $53.09
Upside: -
AnaptysBio
Jul 19, 2018
Initiates: Outperform
Price Target: n/a
Current: $26.34
Upside: -
Mesoblast
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $7.29
Upside: -
Alnylam Pharmaceuticals
Mar 13, 2018
Maintains: Outperform
Price Target: n/a
Current: $150.31
Upside: -
BioMarin Pharmaceutical
Mar 2, 2018
Maintains: Outperform
Price Target: n/a
Current: $83.80
Upside: -
Puma Biotechnology
Jan 24, 2018
Maintains: Outperform
Price Target: n/a
Current: $4.96
Upside: -
Intellia Therapeutics
Nov 3, 2017
Maintains: Outperform
Price Target: n/a
Current: $23.27
Upside: -
Darden Restaurants
Sep 27, 2017
Maintains: Neutral
Price Target: n/a
Current: $147.86
Upside: -
United Therapeutics
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $258.13
Upside: -
AC Immune
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $2.44
Upside: -